Imagine a future where skin diseases like eczema and psoriasis are not just managed, but truly conquered. This is the bold vision driving groundbreaking research in dermatology, and Christopher Bunick, MD, PhD, is at the forefront of this revolution. In a captivating interview with Dermatology Times at the South Beach Symposium 2026 (https://www.dermatologytimes.com/conference/south-beach-symposium), Dr. Bunick, associate professor of dermatology at Yale School of Medicine and editor-in-chief of Dermatology Times, unveiled exciting developments that could transform the way we treat inflammatory skin conditions. His insights reveal a paradigm shift in dermatology, moving towards treatments that are not just effective, but also highly precise and tailored to individual needs.
But here's where it gets controversial: while current biologics have been game-changers for many patients, they often fall short of addressing the full complexity of diseases like atopic dermatitis (AD). As Dr. Bunick pointed out, “AD is a biologically diverse condition, driven by multiple inflammatory pathways, not just one.” This means that single-target biologics, which primarily focus on TH2 cytokines, may not provide complete relief for everyone. Enter bispecific and trispecific biologics—innovative therapies designed to tackle multiple pathways simultaneously. These next-generation treatments aim to deliver deeper skin clearance, better itch and pain management, and significant improvements in quality of life. But will they live up to the hype? Only time and clinical trials will tell.
And this is the part most people miss: beyond biologics, there’s a growing buzz around selective intracellular signaling inhibitors, particularly those targeting tyrosine kinase 2 (TYK2). While TYK2 is part of the Janus kinase (JAK) family, its inhibitors work differently. “The key distinction lies in their target within the JAK enzyme family,” Dr. Bunick explained. Unlike traditional JAK inhibitors that bind to the kinase domain, TYK2 inhibitors act on the regulatory or allosteric domain, offering greater selectivity and fewer off-target effects. This could mean fewer side effects and better long-term safety profiles.
First-generation TYK2 inhibitors, such as deucravacitinib, have already shown impressive results in psoriasis, with over four years of data supporting their efficacy and safety. Dr. Bunick highlighted that these treatments have not shown increased risks for malignancy, cardiovascular events, or venous thromboembolism compared to baseline rates. Next-generation inhibitors like zasocitinib and envudeucitinib promise even greater precision, with phase 3 data for zasocitinib expected soon. While acne-like eruptions and folliculitis remain potential side effects, they are generally manageable.
Here’s a thought-provoking question: Could TYK2 inhibitors be the safer alternative we’ve been waiting for? Dr. Bunick pointed to genetic evidence suggesting that naturally occurring TYK2 variants in humans are associated with lower rates of immune-mediated diseases, further supporting its safety as a therapeutic target. But as with any new treatment, questions remain. How will these inhibitors perform in diverse patient populations? And can they truly revolutionize care for conditions like vitiligo, alopecia areata, dermatomyositis, and hidradenitis suppurativa (HS)?
Speaking of HS, Dr. Bunick called for raising the bar in clinical trials, challenging the field to move beyond modest response rates. “We need therapies that deliver transformative outcomes, not just incremental improvements,” he urged. This bold statement underscores the evolving expectations in dermatology—a field increasingly defined by pathway specificity, enhanced safety, and a relentless pursuit of durable disease control.
As we look to the future, one thing is clear: the landscape of dermatological treatments is changing rapidly. From bispecific biologics to TYK2 inhibitors, these advancements hold the promise of a new era in skin disease management. But what do you think? Are these innovations the answer to unmet needs in dermatology, or is there still room for skepticism? Share your thoughts in the comments below and join the conversation.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
